Jupiter Topco LLC Purchases New Position in Celcuity, Inc. $CELC

Jupiter Topco LLC purchased a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) in the second quarter, according to the company in its most recent filing with the SEC. The fund purchased 7,200 shares of the company’s stock, valued at approximately $754,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC raised its stake in shares of Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after purchasing an additional 319 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after buying an additional 1,167 shares during the last quarter. US Bancorp DE boosted its position in shares of Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares during the last quarter. Parallel Advisors LLC bought a new stake in Celcuity during the first quarter worth $38,000. Finally, Meeder Asset Management Inc. bought a new stake in Celcuity during the fourth quarter worth $42,000. 63.33% of the stock is owned by institutional investors.

Celcuity Price Performance

Shares of NASDAQ:CELC opened at $95.70 on Monday. The company’s 50-day moving average is $94.58 and its 200 day moving average is $106.78. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93. The company has a market capitalization of $4.68 billion, a P/E ratio of -22.26 and a beta of 0.19. Celcuity, Inc. has a fifty-two week low of $44.42 and a fifty-two week high of $151.02.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). On average, equities research analysts forecast that Celcuity, Inc. will post -4.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

CELC has been the subject of several recent analyst reports. Guggenheim increased their target price on shares of Celcuity from $165.00 to $175.00 and gave the company a “buy” rating in a report on Monday, August 17th. Needham & Company LLC cut their price target on shares of Celcuity from $157.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Citigroup reaffirmed a “market outperform” rating on shares of Celcuity in a research report on Monday, August 17th. Stifel Nicolaus dropped their target price on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Finally, Wall Street Zen downgraded Celcuity from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Celcuity presently has a consensus rating of “Moderate Buy” and a consensus price target of $154.55.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.